Invivyd (NASDAQ:IVVD) Insider Julie Green Sells 20,964 Shares

Invivyd, Inc. (NASDAQ:IVVD) insider Julie Green sold 20,964 shares of Invivyd stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total value of $33,123.12. Following the transaction, the insider directly owned 107,717 shares of the company’s stock, valued at $170,192.86. This trade represents a 16.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Julie Green also recently made the following trade(s):

• On Tuesday, February 17th, Julie Green sold 19,663 shares of Invivyd stock. The shares were sold at an average price of $1.54, for a total transaction of $30,281.02.

Invivyd Trading Up 6.5%

Shares of IVVD opened at $1.65 on Thursday. The company has a 50-day moving average of $2.19 and a two-hundred day moving average of $1.75. The stock has a market cap of $384.65 million, a P/E ratio of -3.51 and a beta of 0.60. Invivyd, Inc. has a 12-month low of $0.46 and a 12-month high of $3.07.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Courier Capital LLC purchased a new stake in Invivyd in the fourth quarter valued at approximately $25,000. Bronte Capital Management Pty Ltd. purchased a new stake in shares of Invivyd during the 4th quarter valued at $27,000. DRW Securities LLC acquired a new stake in shares of Invivyd during the 4th quarter worth $27,000. ProShare Advisors LLC purchased a new position in shares of Invivyd in the 4th quarter worth $30,000. Finally, State of Wyoming purchased a new position in shares of Invivyd in the 4th quarter worth $30,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on IVVD shares. BTIG Research reissued a “buy” rating on shares of Invivyd in a report on Wednesday, January 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 29th. D. Boral Capital restated a “hold” rating on shares of Invivyd in a report on Tuesday, November 25th. HC Wainwright lifted their price target on shares of Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, Zacks Research raised shares of Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Invivyd has an average rating of “Hold” and a consensus target price of $8.00.

Trending Headlines about Invivyd

Here are the key news stories impacting Invivyd this week:

• Negative Sentiment: Jill Andersen sold 34,939 shares on Feb. 18 at an average price of $1.58 (≈$55.2k); her holdings fell ~16.1% to 181,736 shares. SEC Filing
• Negative Sentiment: Jill Andersen sold 32,771 shares on Feb. 17 at $1.54 (≈$50.5k); that trade reduced her position by ~13.1%. SEC Filing
• Negative Sentiment: Timothy Edward Lee sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); his stake declined ~15.1% to 117,717 shares. SEC Filing
• Negative Sentiment: Timothy Edward Lee sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); his ownership fell ~12.4%. SEC Filing
• Negative Sentiment: William E. Duke (CFO) sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); his stake dropped ~16.3% to 107,717 shares. SEC Filing
• Negative Sentiment: William E. Duke sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); his position fell ~13.3%. SEC Filing
• Negative Sentiment: Julie Green sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); her holdings declined ~16.3% to 107,717 shares. SEC Filing
• Negative Sentiment: Julie Green sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); that trade lowered her stake ~13.3%. SEC Filing
• Negative Sentiment: Robert D. Allen III sold 19,392 shares on Feb. 18 at $1.58 (≈$30.6k); his holdings fell ~14.5% to 114,487 shares. SEC Filing
• Negative Sentiment: Robert D. Allen III sold 18,189 shares on Feb. 17 at $1.54 (≈$28.0k); his position declined ~12.0%. SEC Filing

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.